Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79728.000.141%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Xeris Biopharma Holdings Inc

XERSNASDAQ
Trade with Public
Trade with Public
$8.53
-0.06-0.7%
At close: Sep 4, 5:00 PM EST
$8.54
0.010.12%
After Hours: Sep 4, 4:15 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Xeris Biopharma Holdings Analyst Price Targets

Wall Street analyst price targets and consensus rating for Xeris Biopharma Holdings (XERS).

Price Target Range — 11 Quarters

Analyst Consensus — 7 Analysts

6Buy
1Hold
Consensus RatingBuy# Analysts7Avg. Consensus PT$10Upside to Avg. PT+20.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 20, 2026BarclaysGlen SantangeloPT RaiseOverweight$9→$12
Mar 2, 2026HC Wainwright & Co.Brandon FolkesMaintainedBuy$10
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $12

Barclays analyst Glen Santangelo maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight and raises the price target from $9 to $12.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Xeris Biopharma Holdings, Maintains $10 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9

Barclays analyst Glen Santangelo initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with a Overweight rating and announces Price Target of $9.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Assumes Xeris Biopharma Holdings at Buy, Announces Price Target of $10

HC Wainwright & Co. analyst Brandon Folkes assumes Xeris Biopharma Holdings (NASDAQ:XERS) with a Buy rating and announces Price Target of $10.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $7

Oppenheimer analyst Leland Gershell maintains Xeris Biopharma Holdings (NASDAQ:XERS) with a Outperform and raises the price target from $6 to $7.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved